Literature DB >> 9180266

Transcriptional activity and constitutive nuclear localization of the ETS protein Elf-1.

I Bredemeier-Ernst1, A Nordheim, R Janknecht.   

Abstract

Elf-1 is a lymphoid-specific transcription factor that belongs to the ETS protein family. It can bind to DNA target sequences within a variety of cytokine genes. We demonstrate that Elf-1 is constitutively localized in the nucleus which is dependent on the presence of amino acids 86-265. Analysis of Gal4-Elf-1 fusion proteins revealed that the N-terminal 86 amino acids of Elf-1 contain a transcriptional activation domain, the activity of which is attenuated by an internal repression domain. Furthermore, Elf-1 interacts specifically with the E74 target sequence and can stimulate transcription driven by the E74 site independent of mitogenic signaling. Thus, Elf-1 is able to stimulate gene transcription which may be required for the development and activity of lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9180266     DOI: 10.1016/s0014-5793(97)00387-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  4 in total

1.  Functional analysis of the transcription factor ER71 and its activation of the matrix metalloproteinase-1 promoter.

Authors:  Luciano De Haro; Ralf Janknecht
Journal:  Nucleic Acids Res       Date:  2002-07-01       Impact factor: 16.971

2.  Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf.

Authors:  Basem S Goueli; Ralf Janknecht
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

3.  The antiproliferative ELF2 isoform, ELF2B, induces apoptosis in vitro and perturbs early lymphocytic development in vivo.

Authors:  Fiona H X Guan; Charles G Bailey; Cynthia Metierre; Patrick O'Young; Dadi Gao; Teh Liane Khoo; Jeff Holst; John E J Rasko
Journal:  J Hematol Oncol       Date:  2017-03-28       Impact factor: 17.388

4.  The ETS transcription factor ELF1 regulates a broadly antiviral program distinct from the type I interferon response.

Authors:  Leon Louis Seifert; Clara Si; Debjani Saha; Mohammad Sadic; Maren de Vries; Sarah Ballentine; Aaron Briley; Guojun Wang; Ana M Valero-Jimenez; Adil Mohamed; Uwe Schaefer; Hong M Moulton; Adolfo García-Sastre; Shashank Tripathi; Brad R Rosenberg; Meike Dittmann
Journal:  PLoS Pathog       Date:  2019-11-04       Impact factor: 6.823

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.